Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

LENZ Therapeutics

Request full access

A San Diego-based late-stage clinical company developing innovative ophthalmic pharmaceutical products to improve vision, with a focus on restoring presbyopia-related near vision loss

Solana Beach, United StatesFounded 2021Biotech & Life Sciences

About LENZ Therapeutics

LENZ Therapeutics is a biopharmaceutical company in the late stages of clinical development, specializing in ophthalmic products to enhance vision. The company is currently focused on the development and commercialization of an aceclidine-based eye drop, known as LNZ100, which is the first of its kind designed to improve near vision in individuals with presbyopia.

As a pre-commercial entity, the company's primary activities revolve around research and development, clinical trials, and securing regulatory approvals for its products. The business model is centered on strategic licensing agreements with established pharmaceutical companies to commercialize its products in specific regions. This is evidenced by their recent exclusive agreements with Laboratoires Théa for the Canadian market and Lotus Pharmaceutical for Korea and other Southeast Asian countries. These agreements provide LENZ with upfront payments, milestone payments, and royalties on net sales, which will be their main source of revenue until their products are fully commercialized.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2021
Headquarters
Solana Beach, United States
Listing
IPO 2024
Sector
Biotech & Life Sciences

LENZ Therapeutics in the Solana Beach ecosystem

Live from Dealroom

The LENZ Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Series B and later1 investor entered at this stage

  • Ridgeback Capital
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about LENZ Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See LENZ Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.